Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Bad financial results growth rate -2.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.6%)
  • Dividend yield for the last twelve months 5.3%
  • Free cash flow yield 7.7% (LTM)
  • Share price is 16.7% higher than minimum and 42.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (22.4x vs
    )

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (-0.1%)46.29
year average price 52.47  


year start price 41.30 2024-07-01

min close price 39.66 2024-07-05

max close price 63.11 2025-03-10

current price 46.29 2025-07-01
Common stocks: 2 111 517 922

Dividend Yield:  5.3%
FCF Yield LTM: 7.7%
EV / LTM EBITDA: 22.4x
EV / EBITDA annualized: 11.5x
Target EV / EBITDA (hist percentile):
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 97 742
Net Debt ($m): 38 895
EV (Enterprise Value): 136 637
EBITDA LTM ($m): 6 108
EV / LTM EBITDA: 22.4x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-30zacks.com

BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?

2025-06-29seekingalpha.com

Bristol-Myers Squibb: You Might Wish You Bought More Now (Upgrade)

2025-06-28247wallst.com

5 of the Safest Strong-Buy High-Yield Dividend Stocks Are On Sale Now

2025-06-26businesswire.com

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

2025-06-25zacks.com

Will New Drugs Enable BMY to Offset the Impact of Generic Competition?

2025-06-16zacks.com

Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to Note

2025-06-13zacks.com

BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?

2025-06-12zacks.com

BMY Reports Positive Data on Sotyktu From Arthritis Study

2025-06-12businesswire.com

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

2025-06-11seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data